- Home
- QLYS vs CPRX Comparison
QLYS vs CPRX Comparison
Compare QLYS & CPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QLYS | CPRX |
|---|---|---|
| Founded | 1999 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.4B |
| IPO Year | 2012 | 2006 |
Fundamental Metrics
Financial Performance| Metric | QLYS | CPRX |
|---|---|---|
| Price | $112.95 | $31.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $133.08 | $35.00 |
| AVG Volume (30 Days) | 729.7K | ★ 2.9M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.99 | ★ 28.24 |
| EPS | ★ 1.42 | 0.50 |
| Revenue | ★ $321,607,000.00 | $119,072,803.00 |
| Revenue This Year | $9.97 | $9.20 |
| Revenue Next Year | $7.15 | $10.51 |
| P/E Ratio | $80.30 | ★ $62.54 |
| Revenue Growth | 15.32 | ★ 16.39 |
| 52 Week Low | $74.51 | $19.05 |
| 52 Week High | $155.47 | $32.56 |
Technical Indicators
Market Signals| Indicator | QLYS | CPRX |
|---|---|---|
| Relative Strength Index (RSI) | 72.05 | 72.39 |
| Support Level | $83.94 | $31.00 |
| Resistance Level | $136.21 | $31.33 |
| Average True Range (ATR) | 4.68 | 0.08 |
| MACD | 1.81 | -0.21 |
| Stochastic Oscillator | 91.81 | 76.39 |
Price Performance
Historical ComparisonAbout QLYS Qualys Inc.
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.